DS-5565 Phase III Study for Post-herpetic Neuralgia

• Status: Completed
• Trial end date: 2017-05-25
• Target enrollment: 0
• Participant gender: All

Summary

Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Co., Ltd.
• Collaborators: Quintiles, Inc.; SRL Medisearch Inc.

Criteria

Inclusion Criteria:

• PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening

• At screening, a pain scale of ≥ 40 mm

Exclusion Criteria:

• Previous use of neurolytic block